Featured Research

from universities, journals, and other organizations

Recurrent Brain Cancer Responds To New Treatment

Date:
March 4, 2008
Source:
University of Virginia Health System
Summary:
One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer. Patients who have a recurrence of this cancer have had no effective therapy -- until now. Researchers have discovered that a compound has shown the ability to effectively treat GBM in some patients.

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer. Patients who have a recurrence of this cancer have had no effective therapy -- until now. Researchers at the University of Virginia and several other leading brain tumor centers nationwide have discovered that a compound has shown the ability to effectively treat GBM in some patients.

Vascular endothelial growth factor (VEGF) has an important biologic role in this disease in fostering tumor growth by facilitating the growth of new blood vessels to feed the tumor. According to earlier studies, bevacizumab (BV), a humanized monoclonal antibody that specifically targets VEGF, in combination with irinotecan (also called CPT-11) could have a role in recurrent glioblastoma multiforme. The researchers set out to determine the clinical benefit of BV, both alone and in combination with CPT-11, in a multicenter, randomized phase II trial.

The results, presented in late 2007 at the 12th annual Society for Neuro-Oncology meeting, were indeed promising for such an intractable disease. Study results substantially exceeded the pre-specified thresholds set for this work.

The primary endpoints were 6-month progression-free survival (PFS) defined as no clinical or MRI tumor growth and the objective response rate (ORR), which measures tumor shrinkage. Secondary endpoints included safety and survival. Response assessments were conducted by a blinded (without access to data on who took which drug(s)) and independent radiographic facility. All patients were followed for 24 weeks to determine efficacy and safety.

Evaluators at this independent facility assessing found that, when taking BV, 35.6 percent of patients on average had a 6-month survival with no progression of their cancer, and an objective response rate of 21.2 percent on average.

The combination of BV and CPT was even more effective, with results of 51 percent and 34.1 percent, respectively.

“Bevacizumab, taken alone or in combination with irinotecan, is well tolerated by most patients,” said Dr. David Schiff, co- director of the UVA Neuro-Oncology Program. “The drug is active in recurrent glioblastoma multiforme that has failed to respond to any prior therapy.”

The investigator group found similar results when they evaluated the patients. Those results showed that 44.7 percent of patients on average had a 6-month survival with no progression of their cancer, and an objective response rate of 38.8 percent on average. The combination therapy yielded results of 60.9 percent and 46.3 percent, respectively.

Patients on the study are still being treated and followed so that longer-term results will become available.

Known also by its brand name, Avastin, bevacizumab has already been approved for the treatment of metastatic colon cancer and most forms of metastatic non-small cell lung cancer.

In addition, UVA is planning and conducting additional brain tumor clinical trials with bevacizumab and other anti-VEGF agents.


Story Source:

The above story is based on materials provided by University of Virginia Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Virginia Health System. "Recurrent Brain Cancer Responds To New Treatment." ScienceDaily. ScienceDaily, 4 March 2008. <www.sciencedaily.com/releases/2008/02/080229172028.htm>.
University of Virginia Health System. (2008, March 4). Recurrent Brain Cancer Responds To New Treatment. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2008/02/080229172028.htm
University of Virginia Health System. "Recurrent Brain Cancer Responds To New Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/02/080229172028.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins